Literature DB >> 11729211

Evaluation of different continuous cell lines in the isolation of mumps virus by the shell vial method from clinical samples.

J Reina1, F Ballesteros, M Mari, M Munar.   

Abstract

AIMS: To compare prospectively the efficacy of the Vero, LLC-MK2, MDCK, Hep-2, and MRC-5 cell lines in the isolation of the mumps virus from clinical samples by means of the shell vial method.
METHODS: During an epidemic outbreak of parotiditis 48 clinical samples (saliva swabs and CSF) were studied. Two vials of the Vero, LLC-MK2, MDCK, MRC-5, and Hep-2 cell lines were inoculated with 0.2 ml of the samples by the shell vial assay. The vials were incubated at 36 degrees C for two and five days. The vials were then fixed with acetone at -20 degrees C for 10 minutes and stained by a monoclonal antibody against mumps virus by means of an indirect immunofluorescence assay.
RESULTS: The mumps virus was isolated from 36 samples. The Vero and LLC-MK2 cell lines showed a 100% isolation capacity, MDCK showed 77.7%, MRC-5 showed 44.4%, and Hep-2 showed 22.2%. The Vero and LLC-MK2 lines were significantly different to the other cell lines (p < 0.001). The sensitivity for the Vero and LLC-MK2 lines at two and five days of incubation was identical (100%). The values obtained in the study of the quantitative isolation capacity (positive isolation with > 5 infectious foci) were 94.4% for Vero, 97.2% for LLC-MK2, 5.5% for MDCK, 5.5% for Hep-2, and 0% for MRC-5.
CONCLUSIONS: The Vero and LLC-MK2 cell lines are equally efficient at two and five days incubation for the isolation of the mumps virus from clinical samples, and the use of the shell vial method considerably shortens the time of aetiological diagnosis with higher specificity.

Entities:  

Mesh:

Year:  2001        PMID: 11729211      PMCID: PMC1731329          DOI: 10.1136/jcp.54.12.924

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  Clinical and laboratory studies of mumps. I. Laboratory diagnosis by tissue-culture technics.

Authors:  J P UTZ; J A KASEL; H G CRAMBLETT; C F SZWED; R H PARROTT
Journal:  N Engl J Med       Date:  1957-09-12       Impact factor: 91.245

2.  Detection of mumps virus in clinical specimens by rapid centrifugation culture and conventional tube cell culture.

Authors:  D Germann; M Gorgievski; A Ströhle; L Matter
Journal:  J Virol Methods       Date:  1998-07       Impact factor: 2.014

3.  Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity.

Authors:  P A Briss; L J Fehrs; R A Parker; P F Wright; E C Sannella; R H Hutcheson; W Schaffner
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

4.  Experiences in laboratory diagnosis of mumps virus infections in routine medical practice.

Authors:  D A Person; T F Smith; E C Herrmann
Journal:  Mayo Clin Proc       Date:  1971-08       Impact factor: 7.616

5.  Determination of IgG- and IgM-class antibodies to mumps virus by solid-phase enzyme immunoassay.

Authors:  O Meurman; P Hänninen; R V Krishna; T Ziegler
Journal:  J Virol Methods       Date:  1982-05       Impact factor: 2.014

  5 in total
  6 in total

1.  Comparison between indirect immunofluorescence assay and shell vial culture for detection of mumps virus from clinical samples.

Authors:  Jordi Reina; Francisca Ballesteros; Enrique Ruiz de Gopegui; Maria Munar; Margarita Mari
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

2.  Rapid diagnostic method for detection of mumps virus genome by loop-mediated isothermal amplification.

Authors:  Takao Okafuji; Naoko Yoshida; Motoko Fujino; Yoshie Motegi; Toshiaki Ihara; Yoshinori Ota; Tsugunori Notomi; Tetsuo Nakayama
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Establishment of a reverse genetics system for studying human bocavirus in human airway epithelia.

Authors:  Qinfeng Huang; Xuefeng Deng; Ziying Yan; Fang Cheng; Yong Luo; Weiran Shen; Diana C M Lei-Butters; Aaron Yun Chen; Yi Li; Liang Tang; Maria Söderlund-Venermo; John F Engelhardt; Jianming Qiu
Journal:  PLoS Pathog       Date:  2012-08-30       Impact factor: 6.823

Review 4.  Saliva and viral infections.

Authors:  Paul L A M Corstjens; William R Abrams; Daniel Malamud
Journal:  Periodontol 2000       Date:  2016-02       Impact factor: 7.589

5.  A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines.

Authors:  Jens-Peter Gregersen
Journal:  Vaccine       Date:  2008-04-15       Impact factor: 3.641

6.  A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine.

Authors:  Jens-Peter Gregersen
Journal:  Vaccine       Date:  2008-04-18       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.